CVS reaffirms FY2022 Adj. EPS guidance at high end; FY2023 Adj. EPS $8.70-$8.90

CVS HEALTH Corp

2022-FY EPS reported $3.14 revenue$322,467,000,000

Reaffirmed FY2022 Adj. EPS guidance $8.55-$8.65; expects high end on lower share count.
Expects to exceed FY2022 revenue guidance of $309B-$314B.
Reaffirmed FY2023 Adj. EPS guidance $8.70-$8.90, excluding Signify Health acquisition.
Repurchased ~15M shares in Q4 2022 at avg $99.99; entered $2B ASR effective Jan 3, 2023.
MA membership growth low-to-mid-single digit % in 2023; individual MA below expectations, exchange memberships >750k.

item 2.02

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVS HEALTH Corp reported full-year 2023 results: EPS $8.70 to $8.90. Guidance reaffirmed.

Period: full-year 2023
EPS: $8.70 to $8.90
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company will also reaffirm its projected full-year 2023 Adjusted EPS guidance range of $8.70 to $8.90

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CVS HEALTH Corp reported full-year 2022 results: EPS $8.55 to $8.65. Guidance reaffirmed.

Period: full-year 2022
EPS: $8.55 to $8.65
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

the Company will disclose that it has reaffirmed its estimated full-year 2022 Adjusted earnings per share ("EPS") guidance range of $8.55 to $8.65

View on SEC.gov

Browse all earnings releases →

CVS HEALTH Corp filing history →

Source: SEC EDGAR

accession 0000064803-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.